TYK Medicines, Inc (HKG:2410)
Hong Kong
· Delayed Price · Currency is HKD 31.05
-1.30 (-4.02%)
Mar 3, 2025, 4:08 PM HKT
TYK Medicines Statistics
Total Valuation
TYK Medicines has a market cap or net worth of HKD 11.51 billion. The enterprise value is 11.48 billion.
| Market Cap | 11.51B |
| Enterprise Value | 11.48B |
Important Dates
The next estimated earnings date is Friday, May 30, 2025.
| Earnings Date | May 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TYK Medicines has 370.84 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 370.84M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +1.64% |
| Owned by Insiders (%) | 2.22% |
| Owned by Institutions (%) | 16.56% |
| Float | 140.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -24.96 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -38.38 |
Financial Position
The company has a current ratio of 0.14
| Current Ratio | 0.14 |
| Quick Ratio | 0.11 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.43 |
| Interest Coverage | -35.63 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 39.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -3.19M |
| Employee Count | 144 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 31.47 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 55.50 |
| Average Volume (20 Days) | 403,805 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -370.49M |
| Pretax Income | -460.80M |
| Net Income | -459.82M |
| EBITDA | -354.89M |
| EBIT | -370.49M |
| Earnings Per Share (EPS) | -1.51 |
Balance Sheet
The company has 170.10 million in cash and 129.71 million in debt, giving a net cash position of 40.39 million or 0.11 per share.
| Cash & Cash Equivalents | 170.10M |
| Total Debt | 129.71M |
| Net Cash | 40.39M |
| Net Cash Per Share | 0.11 |
| Equity (Book Value) | -1.12B |
| Book Value Per Share | -3.03 |
| Working Capital | -1.30B |
Cash Flow
In the last 12 months, operating cash flow was -251.20 million and capital expenditures -47.84 million, giving a free cash flow of -299.04 million.
| Operating Cash Flow | -251.20M |
| Capital Expenditures | -47.84M |
| Free Cash Flow | -299.04M |
| FCF Per Share | -0.81 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TYK Medicines does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -3.99% |
| FCF Yield | -2.60% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |